ArticlePHAGE (New Rochelle, N.Y.)2020
Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research: Personalized Infectious Disease Medicine for the Most Vulnerable At-Risk Patients.
Article in PHAGE (New Rochelle, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Article
- Engineered Phage-Guided Nanotherapeutic Systems for Precision Antibacterial Therapy: Hacking Bacterial Resistance Mechanisms.Pharmaceutics · 2025Review
- Pathogen-Phage Geomapping to Overcome Resistance.bioRxiv : the preprint server for biology · 2025Article
- Exploration of Providers' Perceptions and Attitudes Toward Phage Therapy and Intentions for Future Adoption as an Alternative to Traditional Antibiotics in the US-A Cross-Sectional Study.International journal of environmental research and public health · 2025Article
- Present and future of microbiome-targeting therapeutics.The Journal of clinical investigation · 2025Review
- Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches.The Journal of clinical investigation · 2025Review
- Current status of bacteriophage therapy for severe bacterial infections.Journal of intensive care · 2024Review
- Bacteriophage therapy in musculoskeletal infections: from basic science to clinical application.EFORT open reviews · 2024Review
- The Medicinal Phage-Regulatory Roadmap for Phage Therapy under EU Pharmaceutical Legislation.Viruses · 2024Article
- Addressing the Research and Development Gaps in Modern Phage Therapy.PHAGE (New Rochelle, N.Y.) · 2024Review
- Phage Therapy-Challenges, Opportunities and Future Prospects.Pharmaceuticals (Basel, Switzerland) · 2023Review
- A Retrospective, Observational Study of 12 Cases of Expanded-Access Customized Phage Therapy: Production, Characteristics, and Clinical Outcomes.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Observational
- Data to Power Precision Phage Therapy: A Look at the Phage Directory-Phage Australia Partnership.PHAGE (New Rochelle, N.Y.) · 2022Article
- Discovery of the First LyticPHAGE (New Rochelle, N.Y.) · 2022Article
- Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world.Current opinion in virology · 2022Review
- Identifying Causative Microorganisms in Left Ventricular Assist Device Infections as a Guide for Developing Bacteriophage Therapy.The Journal of surgical research · 2022Article
- Development of Phage Cocktails to TreatFrontiers in microbiology · 2022Article
- Screening for Lysogen Activity in Therapeutically Relevant Bacteriophages.Bio-protocol · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Mutation is the most powerful driver of change for life on Earth. Pathogenic bacteria utilize mutation as a means to survive strong live-die selective pressures generated by chemical antibiotics. As such, the traditional drug-making pipeline, characterized by significant financial and time investment, is insufficient to keep pace with the rapid evolution of bacterial resistance to structurally fixed and chemically unmalleable antibacterial compounds. In contrast, the genetic diversity and adaptive mutability of the bacteriophage can be leveraged to not only overcome resistance but also used for the development of enhanced traits that increase lytic potential and therapeutic efficacy in relevant host microenvironments. This is the fundamental premise behind Baylor College of Medicine's Tailored Antibacterials and Innovative Laboratories for Phage (Φ) Research (TAILΦR) initiative. In this perspective, we outline the concept, structure, and process behind TAILΦR's attempt to generate a personalized therapeutic phage that addresses the most clinically challenging of bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.